Track Indivior PLC — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Indivior PLC INDV.L · Stock Open Indivior PLC in new tab

1238.00 GBX
EPS
-0.04
P/B
-542.98
Beta
0.26
Target Price
1053.34 GBX
Loading chart...
Key Metrics
Earnings dateApril 22, 2026
EPS-0.04
Book Value-2.28
Price to Book-542.98
% Insiders3.882%
Growth
Revenue Growth-0.06%
Earnings Growth-0.16%
Estimates
Forward P/E849.31
Forward EPS1.28
Target Mean Price1053.34

DCF Valuation

Tweak assumptions to recompute fair value for Indivior PLC (INDV.L)
Currency: GBX
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Indivior PLC Logo Indivior PLC Analysis (INDV.L)

United States Health Care Official Website Stock

Is Indivior PLC a good investment? Indivior PLC (INDV.L) is currently trading at 1238.00 GBX. Market analysts have a consensus price target of 1053.34 GBX. This suggests the asset is currently trading above analyst expectations.

Earnings Schedule: Indivior PLC is expected to release its next earnings report on April 22, 2026. The market consensus estimate for Forward EPS is 1.28.

Investor FAQ

Does Indivior PLC pay a dividend?

No, it does not currently pay a dividend.

What asset class is Indivior PLC?

Indivior PLC is classified as a Stock. You can compare it against 7 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be April 22, 2026. The company currently has a trailing EPS of -0.04.

Company Profile

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Exchange Ticker
LSE (United Kingdom) INDV.L
BER (Germany) 2IV.BE
FRA (Germany) 2IV.F
NMS (United States) INDV
MUN (Germany) 2IV.MU
STU (Germany) 2IV.SG
FRA (Germany) 2IVA.F
Trades
Dividend History paid per year (GBX)
Historical Dividends
Year Total Dividends
2016
7.30 GBX
July 29, 2016 7.3000
2015
2.08 GBX
Oct. 23, 2015 2.0800
Stock Splits
Split Date Split Ratio to 1
Oct. 10, 2022 0.200000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion